北陆药业：关于完成工商变更登记并换发营业执照的公告

Core Points - Beilu Pharmaceutical announced the convening of the 9th Board of Directors' fourth meeting on September 25, 2025, and the third extraordinary shareholders' meeting on October 14, 2025, to review the proposal for changing registered capital and amendments [1] - The "Beilu Convertible Bonds" began conversion on June 11, 2021, and triggered conditional redemption on July 14, 2025 [1] - The company decided to redeem all "Beilu Convertible Bonds" at face value plus accrued interest, with trading ceasing on July 31, 2025, and conversion stopping on August 5, 2025 [1] - A total of 71,017,267 shares of "Beilu Pharmaceutical" were converted from the bonds, increasing the total share capital from 491,855,896 shares to 562,873,163 shares [1] - The registered capital changed from 491,855,896 yuan to 562,873,163 yuan, and the company completed the business registration change procedures [1]